60.61
전일 마감가:
$60.58
열려 있는:
$60.41
하루 거래량:
224.40K
Relative Volume:
0.60
시가총액:
$2.10B
수익:
-
순이익/손실:
$-91.00M
주가수익비율:
-16.51
EPS:
-3.67
순현금흐름:
$-74.38M
1주 성능:
+4.92%
1개월 성능:
+12.42%
6개월 성능:
+5.50%
1년 성능:
+38.00%
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
IRON을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IRON
Disc Medicine Inc
|
60.61 | 2.10B | 0 | -91.00M | -74.38M | -3.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-21 | 개시 | Truist | Buy |
2025-07-03 | 재개 | Morgan Stanley | Overweight |
2025-06-11 | 재개 | Raymond James | Strong Buy |
2025-02-27 | 개시 | TD Cowen | Buy |
2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2024-10-23 | 개시 | Jefferies | Buy |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-08-22 | 개시 | Wells Fargo | Overweight |
2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2023-06-07 | 개시 | H.C. Wainwright | Buy |
2023-05-17 | 개시 | Raymond James | Outperform |
2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
2023-04-21 | 개시 | Stifel | Buy |
2023-04-20 | 개시 | Morgan Stanley | Overweight |
2023-03-23 | 개시 | BMO Capital Markets | Outperform |
2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Insider Selling at Disc Medicine Inc.: A Balancing Act Between Portfolio Strategy and Investor Sentiment - AInvest
Is Disc Medicine Inc. a good long term investmentFree Stock Movement Tracking - PrintWeekIndia
Can Disc Medicine Inc. stock recover from recent declineSuperior profit margins - jammulinksnews.com
What drives Disc Medicine Inc. stock priceBreakthrough capital growth - PrintWeekIndia
10 Best Mid Cap Stocks to Buy According to Billionaires - Insider Monkey
Is Disc Medicine Inc. stock overhyped or has real potentialBreakthrough wealth creation - jammulinksnews.com
Disc Medicine Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - Autocar Professional
What analysts say about Disc Medicine Inc. stockUnrivaled growth potential - Autocar Professional
Disc Medicine’s Strategic Advancements and Regulatory Progress Drive Buy Rating - TipRanks
Disc Medicine To Seek FDA Approval For Bitopertin In EPP, A Painful Sunlight Sensitivity Disorder - Nasdaq
Disc Medicine’s (IRON) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Disc Medicine's NDA Submission for Bitopertin in EPP: A Catalyst-Driven Opportunity in a High-Unmet-Need Market - AInvest
Disc Medicine to submit NDA for bitopertin in EPP in October By Investing.com - Investing.com India
Truist Securities initiates Disc Medicine stock with Buy rating, $86 target - Investing.com Canada
Disc Medicine to submit NDA for bitopertin in EPP in October - Investing.com Australia
Disc Medicine, Inc. Receives Positive FDA Feedback for Bitopertin NDA Submission in Erythropoietic Protoporphyria - Nasdaq
Disc Medicine Announces Positive Pre-NDA Meeting and - GlobeNewswire
why disc medicine inc. stock attracts strong analyst attentionReal Time Stock Signal - Newser
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85 - 富途牛牛
Disc Medicine(IRON) Soars 7.28% on Insider Trading, Analyst Rating - AInvest
Disc medicine CFO Franchi sells $119k in shares - Investing.com
Disc medicine CFO Franchi sells $119k in shares By Investing.com - Investing.com India
Raymond James reiterates Strong Buy on Disc Medicine stock amid Bristol Myers trial results - Investing.com Canada
Why Disc Medicine Inc. stock attracts strong analyst attentionMarket Ready Callouts - Newser
How Disc Medicine Inc. stock performs during market volatilityCapital Safe Stock Watchlist - Newser
What makes Disc Medicine Inc. stock price move sharplyRisk Adjusted Stock Signals - Newser
Disc Medicine Elects Nadim Ahmed as Director - The Globe and Mail
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):